Intravenous thrombolytic therapy in patients with stroke mimics: Baseline characteristics and safety profile

European Journal of Neurology

Volumn 18, Issue 10, 2011, Pages 1246-1250

  Chen, Y ^a,b   Bogosavljevic, V ^c,d   Leys, D ^a,b   Jovanovic, D ^c,d   Beslac Bumbasirevic, L ^c,d   Lucas, C ^a,b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Institute of Neurology   (Serbia)

^d UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Angioneurotic oedema; Intracranial haemorrhage; Ischemic stroke; RtPA; Stroke mimics

Indexed keywords

FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BELL PALSY; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE AURA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; RANKIN SCALE; SOMATOFORM DISORDER; STROKE; STROKE PATIENT; TODDLER; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; DIAGNOSTIC ERRORS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 80052409536     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03367.x     Document Type: Article

References (22)

1. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-607.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 1995; 333: 1581-1587.
3. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
4. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
5. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
6. The-European-Stroke-Organisation- (ESO)-Executive-Committee-and-the-ESO-Writing-Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008 (update 2009). 2009.
7. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40: 2945-2948.
8. Sobesky J, Frackowiak M, Zaro Weber O, et al. The cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis. Cerebrovasc Dis 2007; 24: 56-65.
9. Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study (CASES). CMAJ 2005; 172: 1307-1312.
10. Bateman BT, Schumacher HC, Boden-Albala B, et al. Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002. Stroke 2006; 37: 440-446.
11. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
12. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4.5h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372: 1303-1309.
13. Cordonnier C, Girot M, Dorp E, et al. Stroke units from scientific evidence to practice: the experience of the Lille stroke unit. Cerebrovasc Dis 2000; 10(Suppl. 4): 17-20.
14. Winkler DT, Fluri F, Fuhr P, et al. Thrombolysis in stroke mimics: frequency, clinical characteristics, and outcome. Stroke 2009; 40: 1522-1525.
15. Chernyshev OY, Martin-Schild S, Albright KC, et al. Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology 2010; 74: 1340-1345.
16. Scott PA, Silbergleit R. Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes. Ann Emerg Med 2003; 42: 611-618.
17. Engelter ST, Fluri F, Buitrago-Tellez C, et al. Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke. J Neurol 2005; 252: 1167-1170.
18. Bodenant M, Leys D, Debette S, et al. Intravenous thrombolysis for acute cerebral ischaemia: comparison of outcomes between patients treated at working versus nonworking hours. Cerebrovasc Dis 2010; 30: 148-156.
19. Jovanovic DR, Beslac-Bumbasirevic L, Budimkic M, Pekmezovic T, Zivkovic M, Kostic VS. Do women benefit more from systemic thrombolysis in acute ischemic stroke? A Serbian experience with thrombolysis in ischemic stroke (SETIS) study. Clin Neurol Neurosurg 2009; 111: 729-732.
20. The-European-Stroke-Organisation- (ESO)-Executive-Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
21. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
22. Grimm SA, DeAngelis LM. Intratumoral hemorrhage after thrombolysis in a patient with glioblastoma multiforme. Neurology 2007; 69: 936.